Dividend Investing Ideas Center
Critical Facts You Need to Know About Preferred Stocks
Have you ever wished for the safety of bonds, but the return potential...
You take care of your investments. We like that.
Upgrade to Premium to access your Watchlist and more.
Range Cancer Therapeutics ETF
ETF
CNCR
Payout Change
Suspended
Price as of:
$13.35
-0.04
-0.3%
primary theme
Health Care Sector Equity
CNCR (ETF)
Range Cancer Therapeutics ETF
Payout Change
Suspended
Price as of:
$13.35
-0.04
-0.3%
primary theme
Health Care Sector Equity
CNCR (ETF)
Range Cancer Therapeutics ETF
Payout Change
Suspended
Price as of:
$13.35
-0.04
-0.3%
primary theme
Health Care Sector Equity
Name
As of 11/18/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
Vitals
YTD Return
-0.6%
1 yr return
25.7%
3 Yr Avg Return
-20.2%
5 Yr Avg Return
-7.4%
Net Assets
$28.7 M
Holdings in Top 10
25.4%
52 WEEK LOW AND HIGH
$13.4
$10.50
$17.84
Expenses
OPERATING FEES
Expense Ratio 0.79%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 58.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
N/A
IRA
N/A
Fund Classification
Fund Type
Exchange Traded Fund
Name
As of 11/18/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
CNCR - Profile
Distributions
- YTD Total Return -0.6%
- 3 Yr Annualized Total Return -20.2%
- 5 Yr Annualized Total Return -7.4%
- Capital Gain Distribution Frequency N/A
- Net Income Ratio -0.37%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annual
Fund Details
-
Legal NameRange Cancer Therapeutics ETF
-
Fund Family NameLoncar Investments
-
Inception DateOct 13, 2015
-
Shares Outstanding1450000
-
Share ClassN/A
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerAustin Wen
Fund Description
The Fund uses a “passive management” (or indexing) approach to track the performance, before fees and expenses, of the Index.
Range Cancer Therapeutics Index
The Index was established in 2023 by Range Fund Holdings (the “Index Provider”) and tracks the performance of a portfolio of approximately 85 U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts (“ADRs”) with a market capitalization of more than $250 million. To be eligible for inclusion in the Index, companies must either derive (i) 50% or more of their commercial revenue from oncology products or (ii) 50% or more of their pipeline value (as defined by the Index Provider) from oncology drugs in development (collectively, “Cancer Therapeutics Companies”). Companies based in China are not eligible for inclusion in the Index. The Index is equal-weighted at the time of its semi-annual reconstitution and rebalance, which takes place on the third Tuesday of June and December.
The Fund’s Investment Strategy
The Fund attempts to invest all, or substantially all, of its assets in the component securities that make up the Index. Under normal circumstances, at least 80% of the Fund’s total assets (exclusive of any collateral held from securities lending) will be invested in the component securities of the Index. Exchange Traded Concepts, LLC (“ETC” or the “Adviser”), the Fund’s investment adviser, expects that, over time, the correlation between the Fund’s performance and that of the Index, before fees and expenses, will be 95% or better.
The Fund will generally use a “replication” strategy to achieve its investment objective, meaning it generally will invest in all of the component securities of the Index. However, the Fund may use a “representative sampling” strategy, meaning it may invest in a sample of the securities in the Index whose risk, return and other characteristics closely resemble the risk, return
and other characteristics of the Index as a whole, when the Adviser believes it is in the best interests of the Fund (e.g., when replicating the Index involves practical difficulties or substantial costs, an Index constituent becomes temporarily illiquid, unavailable or less liquid, or as a result of legal restrictions or limitations that apply to the Fund but not to the Index).
The Fund generally may invest up to 20% of its total assets (exclusive of any collateral held from securities lending) in securities or other investments not included in the Index, but which the Adviser believes will help the Fund track the Index. For example, the Fund may invest in securities that are not components of the Index to reflect various corporate actions and other changes to the Index (such as reconstitutions, additions and deletions).
To the extent the Index concentrates (i.e., holds more than 25% of its total assets) in the securities of a particular industry or group of related industries, the Fund will concentrate its investments to approximately the same extent as the Index.
CNCR - Performance
Return Ranking - Trailing
| Period | CNCR Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -0.6% | -30.9% | 18.3% | 87.42% |
| 1 Yr | 25.7% | -17.8% | 49.5% | 10.06% |
| 3 Yr | -20.2%* | -31.7% | 8.3% | 98.03% |
| 5 Yr | -7.4%* | -7.4% | 12.0% | 100.00% |
| 10 Yr | N/A* | 0.1% | 13.0% | 68.07% |
* Annualized
Return Ranking - Calendar
| Period | CNCR Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | -1.9% | -12.6% | 19.0% | 79.25% |
| 2022 | -42.3% | -53.9% | 3.2% | 98.68% |
| 2021 | -25.0% | -39.6% | 24.2% | 92.11% |
| 2020 | 35.3% | -13.6% | 178.2% | 9.40% |
| 2019 | 24.2% | 3.8% | 63.8% | 28.57% |
Total Return Ranking - Trailing
| Period | CNCR Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -0.6% | -30.9% | 18.3% | 87.42% |
| 1 Yr | 25.7% | -17.8% | 49.5% | 10.06% |
| 3 Yr | -20.2%* | -31.7% | 8.3% | 98.03% |
| 5 Yr | -7.4%* | -7.4% | 12.0% | 100.00% |
| 10 Yr | N/A* | 0.1% | 13.0% | N/A |
* Annualized
Total Return Ranking - Calendar
| Period | CNCR Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | -1.9% | -12.6% | 19.0% | 86.79% |
| 2022 | -42.3% | -53.9% | 3.7% | 99.34% |
| 2021 | -19.1% | -33.9% | 26.0% | 98.03% |
| 2020 | 36.5% | -0.7% | 180.6% | 20.81% |
| 2019 | 24.2% | 4.6% | 63.8% | 63.16% |
CNCR - Holdings
Concentration Analysis
| CNCR | Category Low | Category High | CNCR % Rank | |
|---|---|---|---|---|
| Net Assets | 28.7 M | 6.66 M | 45.7 B | 82.39% |
| Number of Holdings | 76 | 26 | 430 | 55.97% |
| Net Assets in Top 10 | 3.37 M | 2.12 M | 22.1 B | 93.71% |
| Weighting of Top 10 | 25.41% | 18.4% | 79.7% | 93.71% |
Top 10 Holdings
- Summit Therapeutics Inc 3.83%
- Geron Corp 3.80%
- Enliven Therapeutics Inc 2.66%
- Acrivon Therapeutics Inc 2.62%
- Nurix Therapeutics Inc 2.51%
- iTeos Therapeutics Inc 2.20%
- Nuvation Bio Inc 2.06%
- Erasca Inc 1.95%
- Foghorn Therapeutics Inc 1.92%
- REVOLUTION Medicines Inc 1.87%
Asset Allocation
| Weighting | Return Low | Return High | CNCR % Rank | |
|---|---|---|---|---|
| Stocks | 99.85% | 87.34% | 106.13% | 13.21% |
| Cash | 0.22% | 0.00% | 33.01% | 88.05% |
| Preferred Stocks | 0.00% | 0.00% | 7.86% | 59.12% |
| Other | 0.00% | -22.99% | 23.24% | 61.01% |
| Convertible Bonds | 0.00% | 0.00% | 0.37% | 43.51% |
| Bonds | 0.00% | 0.00% | 12.39% | 56.60% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | CNCR % Rank | |
|---|---|---|---|---|
| Healthcare | 100.00% | 59.26% | 100.00% | 22.08% |
| Utilities | 0.00% | 0.00% | 0.00% | 39.61% |
| Technology | 0.00% | 0.00% | 22.69% | 44.16% |
| Real Estate | 0.00% | 0.00% | 5.89% | 43.51% |
| Industrials | 0.00% | 0.00% | 7.02% | 43.51% |
| Financial Services | 0.00% | 0.00% | 1.60% | 57.14% |
| Energy | 0.00% | 0.00% | 0.00% | 39.61% |
| Communication Services | 0.00% | 0.00% | 9.11% | 42.86% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 46.75% |
| Consumer Cyclical | 0.00% | 0.00% | 1.92% | 43.51% |
| Basic Materials | 0.00% | 0.00% | 7.16% | 59.74% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | CNCR % Rank | |
|---|---|---|---|---|
| US | 99.85% | 66.06% | 104.41% | 10.69% |
| Non US | 0.00% | 0.00% | 28.87% | 81.13% |
CNCR - Expenses
Operational Fees
| CNCR Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.79% | 0.08% | 4.48% | 68.55% |
| Management Fee | 0.79% | 0.03% | 1.25% | 67.92% |
| 12b-1 Fee | 0.00% | 0.00% | 1.00% | 6.49% |
| Administrative Fee | N/A | 0.03% | 0.25% | N/A |
Sales Fees
| CNCR Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 1.00% | N/A |
Trading Fees
| CNCR Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| CNCR Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 58.00% | 0.00% | 238.00% | 63.70% |
CNCR - Distributions
Dividend Yield Analysis
| CNCR | Category Low | Category High | CNCR % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 6.24% | 59.75% |
Dividend Distribution Analysis
| CNCR | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annual | Annual | Annual | Annual |
Net Income Ratio Analysis
| CNCR | Category Low | Category High | CNCR % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.37% | -2.54% | 1.85% | 61.84% |
Capital Gain Distribution Analysis
| CNCR | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Semi-Annually | Annually |
Distributions History
| Date | Amount | Type |
|---|---|---|
| Dec 29, 2021 | $1.853 | OrdinaryDividend |
| Dec 30, 2020 | $0.288 | OrdinaryDividend |
| Dec 28, 2017 | $0.350 | OrdinaryDividend |
| Dec 29, 2015 | $0.106 | OrdinaryDividend |
CNCR - Fund Manager Analysis
Managers
Austin Wen
Start Date
Tenure
Tenure Rank
Dec 31, 2018
3.42
3.4%
Austin Wen, CFA has seven years of investment management experience. Mr. Wen is a Portfolio Manager at Vident, specializing in portfolio management and trading of equity portfolios and commodities based portfolios, as well as risk monitoring and investment analysis. Previously, Mr. Wen was an analyst for Vident Financial, working on the development and review of investment solutions. He began his career as a State Examiner for the Georgia Department of Banking and Finance. Mr. Wen obtained a BA in Finance from the University of Georgia and holds the Chartered Financial Analyst designation.
Rafael Zayas
Start Date
Tenure
Tenure Rank
Jun 19, 2020
1.95
2.0%
Rafael Zayas, CFA, is Senior Vice President, Head of Portfolio Management and Trading at Vident Investment Advisory, LLC since June 2020. Mr. Zayas became SVP, Head of Portfolio Management and Trading in June 2020. From 2017 to 2020, he was a Senior Portfolio Manager – International Equity at Vident and has over 15 years of experience that includes managing international equity portfolios, including in emerging and frontier markets. Prior to joining Vident, he was a Portfolio Manager – Direct Investments for seven years at Russell Investments, a global asset manager, where he co-managed more than $4 billion in quantitative strategies across global markets, including the Russell Strategic Call Overwriting Fund, a mutual fund. Mr. Zayas also helped Russell Investments launch its sponsored ETF initiative and advised on index methodologies. Prior to joining Russell Investments, Mr. Zayas was a Portfolio Manager – Equity Indexing at Mellon Capital Management, where he managed assets for internationally listed global equity ETFs. Mr. Zayas graduated with a B.S. in Electrical Engineering from Cornell University and obtained a Certificate in Computational Finance and Risk Management from the University of Washington. He also attained the Chartered Financial Analyst designation in 2010.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 7.88 | 0.25 |
